Back to Search
Start Over
Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: the TERICAM study.
- Source :
- Neurology perspectives; 20230101, Issue: Preprints
- Publication Year :
- 2023
-
Abstract
- Introduction and objective: Teriflunomide is an oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). We examined teriflunomide outcomes in patients with RRMS under clinical practice conditions in Spain.
Details
- Language :
- English
- ISSN :
- 26670496
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Neurology perspectives
- Publication Type :
- Periodical
- Accession number :
- ejs64145126
- Full Text :
- https://doi.org/10.1016/j.neurop.2023.100133